- +91-8624883983
- info@insightsmicro.com
In vitro diagnostics - statistics & facts
Sdafdsaf
The global in vitro diagnostics (IVD) market experienced significant growth, rising from $116.7 billion in 2024 to $156.39 billion by 2029, with a compound annual growth rate (CAGR) of 5%. Experts anticipate that the rise in chronic and infectious diseases, advancements in diagnostic technologies and applications, and the trend toward personalized medicine will significantly contribute to this growth in allergic diseases. The latest news indicates that LabCorp excelled throughout Q2 2024, despite a $103 million COVID impact. The company not only met its revenue target of $3.22 billion but also increased its sales growth forecast for the 2024 period from 6.4% to 7.5%. Similarly, Cepheid surpassed forecasts of $100 million in net sales during Q2 2024, exhibiting outstanding market positions, whereas the Danaher Molecular Test surpassed all projections for the quarter. These trends will enhance the significance and spread of IVD in modern healthcare.
The global in vitro diagnostics (IVD) market experienced significant growth, rising from $116.7 billion in 2024 to $156.39 billion by 2029, with a compound annual growth rate (CAGR) of 5%. Experts anticipate that the rise in chronic and infectious diseases, advancements in diagnostic technologies and applications, and the trend toward personalized medicine will significantly contribute to this growth in allergic diseases. The latest news indicates that LabCorp excelled throughout Q2 2024, despite a $103 million COVID impact. The company not only met its revenue target of $3.22 billion but also increased its sales growth forecast for the 2024 period from 6.4% to 7.5%. Similarly, Cepheid surpassed forecasts of $100 million in net sales during Q2 2024, exhibiting outstanding market positions, whereas the Danaher Molecular Test surpassed all projections for the quarter. These trends will enhance the significance and spread of IVD in modern healthcare.
The global in vitro diagnostics (IVD) market experienced significant growth, rising from $116.7 billion in 2024 to $156.39 billion by 2029, with a compound annual growth rate (CAGR) of 5%. Experts anticipate that the rise in chronic and infectious diseases, advancements in diagnostic technologies and applications, and the trend toward personalized medicine will significantly contribute to this growth in allergic diseases. The latest news indicates that LabCorp excelled throughout Q2 2024, despite a $103 million COVID impact. The company not only met its revenue target of $3.22 billion but also increased its sales growth forecast for the 2024 period from 6.4% to 7.5%. Similarly, Cepheid surpassed forecasts of $100 million in net sales during Q2 2024, exhibiting outstanding market positions, whereas the Danaher Molecular Test surpassed all projections for the quarter. These trends will enhance the significance and spread of IVD in modern healthcare.
